TY - JOUR
T1 - Treatment of B-Cell Lymphoproliferative Disorders with Interferon Alfa and Intravenous Gamma Globulin
AU - Shapiro, Ralph S.
AU - Chauvenet, Allen
AU - Mcguire, Warren
AU - Pearson, Andrew
AU - Craft, Alan W.
AU - Mc Glave, Philip B
AU - Filipovich, Alexandra
PY - 1988/5/19
Y1 - 1988/5/19
N2 - To the Editor: Immunodeficiency predisposes patients to B-cell lymphoproliferative disorders (BLPD), which are frequently associated with the Epstein–Barr virus, are often fatal,1 2 and are resistant to conventional therapy with irradiation, chemotherapy, and antiviral agents.34 In immunocompromised hosts, BLPD ranges histologically from polymorphic B-cell hyperplasia to immunoblastic sarcoma. These disorders differ in both cause and biologic features from non-Hodgkin's lymphoma arising in immunocompetent patients.5 Whether polyclonal or monoclonal, all are clinically aggressive and may result in death from organ failure due to infiltration by rapidly dividing cells. We recently observed dramatic responses in five patients with BLPD treated with interferon alfa.
AB - To the Editor: Immunodeficiency predisposes patients to B-cell lymphoproliferative disorders (BLPD), which are frequently associated with the Epstein–Barr virus, are often fatal,1 2 and are resistant to conventional therapy with irradiation, chemotherapy, and antiviral agents.34 In immunocompromised hosts, BLPD ranges histologically from polymorphic B-cell hyperplasia to immunoblastic sarcoma. These disorders differ in both cause and biologic features from non-Hodgkin's lymphoma arising in immunocompetent patients.5 Whether polyclonal or monoclonal, all are clinically aggressive and may result in death from organ failure due to infiltration by rapidly dividing cells. We recently observed dramatic responses in five patients with BLPD treated with interferon alfa.
UR - http://www.scopus.com/inward/record.url?scp=0023914384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023914384&partnerID=8YFLogxK
U2 - 10.1056/NEJM198805193182013
DO - 10.1056/NEJM198805193182013
M3 - Letter
C2 - 3258958
AN - SCOPUS:0023914384
SN - 0028-4793
VL - 318
SP - 1334
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 20
ER -